References
- Antunes G, Neville E, Duffy J, . BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58(Suppl. 2):ii29–ii38.
- Schmidt HH, Renner H, Linkesch W, . Intrapleural instillation of rituximab for the treatment of malignant pleural effusions in NHL. Haematologica 2004;89:ECR39.
- Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
- Pfreundschuh M, Schubert J, Ziepert M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
- Coiffier B, Thieblemont C, Van Den Neste E, Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040–2045.
- Crysandt M, Neumann B, Das M, . Intraperitoneal application of rituximab in refractory mantle cell lymphoma with massive ascites resulting in local and systemic response. Eur J Haematol 2007;79: 546–549.
- Ng T, Pagliuca A, Mufti GJ. Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Ann Hematol 2002;81:405–406.
- Ferreri AJ, Govi S, Colucci A, . Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology 2011;118:24–28.
- Kyrtsonis MC, Siakantaris MP, Kalpadakis C, . Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol 2006;77:300–303.
- Fink-Puches R, Wolf IH, Zalaudek I, . Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol 2005;52:847–853.
- Paul T, Radny P, Kröber SM, . Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 2001;144:1239–1243.
- Schulz H, Pels H, Schmidt-Wolf I, . Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004;89:753–754.
- Rubenstein JL, Combs D, Rosenberg J, . Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466–468.